Mapping the metabolic impact of pancreatic cancer treatment

In a 2026 study with pancreatic cancer patients, our team identified significant reductions in lipid metabolite abundance in tumour tissue and serum following neoadjuvant FOLFIRINOX chemotherapy — providing new molecular insight into how treatment affects lipid metabolism.

Amrutkar et al., Metabolomics (2026). DOI: 10.1007/s11306-025-02388-z

First metabolomics study of rare poisoning in Norway

Our group reported the first case of 3-nitropropionic acid (3-NPA) intoxication in Norway — and only the second in Scandinavia — using our global metabolomics platform, demonstrating how untargeted metabolomics can detect rare toxic exposures that conventional tests would miss.

Skogvold et al. (2021), Journal of Applied Toxicology.

Sepsis biomarker discovery through lipidomics

Ongoing PhD work in our group is applying global lipidomics and metabolomics to investigate the host response to sepsis-causing infections, with the aim of identifying novel biomarkers for earlier and more accurate sepsis diagnosis.

Dry eye disease — a metabolomic perspective

In collaboration with the Norwegian Dry Eye Clinic, our team is applying metabolomics and lipidomics to tear fluid and plasma samples to investigate the molecular basis of dry eye disease and identify potential diagnostic biomarkers.